This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Surface Oncology 将来の成長

Future 基準チェック /06

現在、 Surface Oncologyの成長と収益を予測するのに十分なアナリストの調査がありません。

主要情報

9.9%

収益成長率

9.9%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	75.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	08 Sep 2023

今後の成長に関する最新情報

Recent updates

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Nov 07

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Aug 08

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Aug 03

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

May 25

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

May 11

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Mar 15

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Feb 16

Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets

Dec 09

What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?

Dec 08

Surface Oncology shares rise 13% on Fast Track tag for SRF388

Nov 11

業績と収益の成長予測

NasdaqCM:SURF - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	16	-75	N/A	N/A	2
12/31/2024	N/A	-90	N/A	N/A	2
12/31/2023	N/A	-90	N/A	N/A	1
6/30/2023	N/A	-93	-84	-84	N/A
3/31/2023	N/A	-90	-60	-59	N/A
12/31/2022	30	-64	-60	-60	N/A
9/30/2022	30	-66	-54	-54	N/A
6/30/2022	31	-63	-50	-50	N/A
3/31/2022	31	-57	-67	-67	N/A
12/31/2021	3	-78	-62	-62	N/A
9/30/2021	90	13	26	26	N/A
6/30/2021	90	17	31	31	N/A
3/31/2021	89	21	27	27	N/A
12/31/2020	126	59	30	30	N/A
9/30/2020	39	-24	-56	-56	N/A
6/30/2020	39	-25	-60	-60	N/A
3/31/2020	40	-28	-58	-57	N/A
12/31/2019	15	-55	-62	-60	N/A
9/30/2019	25	-44	-63	-61	N/A
6/30/2019	26	-44	-61	-58	N/A
3/31/2019	28	-35	-65	-63	N/A
12/31/2018	59	-7	-15	-13	N/A
9/30/2018	52	-18	-15	-14	N/A
6/30/2018	53	-15	-12	-11	N/A
3/31/2018	57	-13	21	22	N/A
12/31/2017	13	-45	-14	-12	N/A
9/30/2017	12	-36	-13	-11	N/A
12/31/2016	7	-17	N/A	41	N/A

アナリストによる今後の成長予測

収入対貯蓄率: SURF今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SURF今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SURF今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SURF来年は収益がないと予測されています。

高い収益成長: SURF来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: SURFの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

This company has been acquired

Surface Oncology 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 17%, EPS upgraded

Price target decreased to US$5.25

Consensus forecasts updated

Consensus revenue estimates increase by 46%

Price target decreased to US$13.00

Consensus forecasts updated

Recent updates

Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others.

Nasdaq Approves Surface Oncology, Inc.'s Common Stock Transfer the Listing from the Nasdaq Global Market to the Nasdaq Capital Market

Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million.

Consensus revenue estimates decrease by 17%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Surface Oncology Receives A Deficiency Letter from the Nasdaq Regarding Minimum Bid Price Requirement

Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology

Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors

Price target decreased to US$5.25

Consensus forecasts updated

Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.44 loss in 3Q 2021)

Surface Oncology to Present Preclinical Data Highlighting the IL-27 Gene Expression Signature in Treatment-Resistant Cancers at the 10th Annual International Cytokine and Interferon Society Meeting

Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Surface Oncology GAAP EPS of -$0.46 misses by $0.01

Surface Oncology Appoints Carsten Brunn to Board of Directors

Surface Oncology, Inc. Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma

Surface Oncology, Inc. Presents New SRF388 Clinical Data At 2022 American Society of Clinical Oncology Annual Meeting

Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline

Consensus revenue estimates increase by 46%

News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surface Oncology, Inc. to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting

Price target decreased to US$13.00

Surface Oncology, Inc. Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study

Consensus forecasts updated

Price target decreased to US$14.75

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Surface Oncology Announces Stepping Down of Geoffrey McDonough from the Board of Directors

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Surface Oncology to Present New Clinical Data from Ongoing SRF617 Phase 1 Trial at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562

Investor sentiment deteriorated over the past week

Is Surface Oncology (NASDAQ:SURF) A Risky Investment?

Surface Oncology: Staying The Course

Investor sentiment improved over the past week

Consensus revenue estimates fall to US$21.0m

Investor sentiment deteriorated over the past week

Surface Oncology: A Diverse, But Early Pipeline

Chairman of the Board exercised options and sold US$862k worth of stock

Investor sentiment deteriorated over the past week

Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?

Surface Oncology Announces the Presentation of New Data from the Ongoing Phase 1 Studies of SRF388 and SRF617

Investor sentiment improved over the past week

Consensus revenue estimates increase to US$28.1m

First quarter 2021 earnings released: US$0.37 loss per share (vs US$0.81 profit in 1Q 2020)

Surface Oncology EPS beats by $0.04, beats on revenue

Surface Oncology, Inc. (NasdaqGM:SURF) acquired worldwide, exclusive, sublicensable license of Vaccinex, Inc. (NasdaqCM:VCNX).

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Analysts lower revenue estimates to US$18.8m

Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS US$1.67 (vs US$1.97 loss in FY 2019)

Surface Oncology Collaborates with Merck on Immuno-Oncology Study Evaluating SRF388, Targeting IL-27, in Combination with KEYTRUDA in Patients with Solid Tumors

New 90-day low: US$7.53

Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?

Surface Oncology, Inc. Announces Resignation of Daniel S. Lynch as Member and Chairman, Effective April 1, 2021

Surface Oncology, Inc. Announces Executive Changes, Effective April 1, 2021

CEO, President & Director notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

New 90-day high: US$10.70

Analysts update estimates

Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program